Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inhibitex reports marginal increase in Q4 net loss
For the 12 months ended December 31, 2008, the company reported a net loss of $13.16 million, or $0.31 per share, compared to a net loss of $41.46
For the 12 months ended December 31, 2008, the company reported a net loss of $13.16 million, or $0.31 per share, compared to a net loss of $41.46
For the year ended December 31, 2008, net loss was $44.7 million, or $1.51 per share, compared to a net loss of $43.7 million, or $1.60 per share,
Roche and Genentech, a biotechnology company, have signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for $95 per share in
An EUA authorizes the use of unapproved medical products or unapproved uses of approved medical products during a declared public health emergency. “The FDA worked quickly with the
“Dave brings to Med BioGene over twenty years of experience in funding and operating life science companies. We are on track to launch LungExpress Dx(TM) in the second
PolyMedix, a biotechnology company, has successfully completed its first-in-man clinical study with the novel heparin antagonist drug PMX-60056. This ascending single-dose intravenous pharmacokinetic and safety study met the
Under the agreement, the three parties will jointly conduct a series of biomarker discovery studies for heart disease and early detection of metabolic syndrome – a combination of
It is reported that Technimed’s magnetic resonance imaging (MRI) technology and product Oxy-17 effectively renders an unaltered MRI scanner into a positron emission tomography (PET), PET/CT like metabolic
ImmunoCellular Therapeutics or IMUC, a biotechnology company, has signed an agreement with Formatech, a provider of product development and aseptic fill finish manufacturing services, for the development of
Vyteris, a biotechnology company, has initiated a Phase II clinical trial sponsored by its development partner, Ferring Pharmaceuticals. The trial evaluates Vyteris’s smart patch technology for the safety